Rimonabant, a selective cannabinoid CB1 receptor antagonist, inhibits atherosclerosis in LDL receptor-deficient mice
| Autor: | Réjane Paumelle, Paul Schaeffer, Françoise Bono, Andries J. Gilde, Nathalie Hennuyer, Perrine Desitter, Bart Staels, Anne-Marie Mares, Virgile Visentin, Frédérique Dol-Gleizes |
|---|---|
| Rok vydání: | 2008 |
| Předmět: |
medicine.medical_specialty
Cannabinoid receptor medicine.medical_treatment Article Proinflammatory cytokine chemistry.chemical_compound Mice Rimonabant Piperidines Receptor Cannabinoid CB1 Internal medicine medicine Animals Chemokine CCL2 Inflammation Mice Knockout Cholesterol Cannabinoids Antagonist Atherosclerosis Interleukin-12 Endocrinology chemistry Receptors LDL Low-density lipoprotein LDL receptor Cytokines Pyrazoles Female Cannabinoid Cardiology and Cardiovascular Medicine Energy Intake medicine.drug |
| Zdroj: | Arteriosclerosis, thrombosis, and vascular biology. 29(1) |
| ISSN: | 1524-4636 |
| Popis: | Objective— The objective of this study was to determine whether the potent selective cannabinoid receptor-1 antagonist rimonabant has antiatherosclerotic properties. Methods and Results— Rimonabant (50 mg/kg/d in the diet) significantly reduced food intake (from 3.35±.04 to 2.80±0.03 g/d), weight gain (from 14.6±0.7 g to −0.6±0.3 g), serum total cholesterol (from 8.39±0.54 to 5.32±0.18 g/L), and atherosclerotic lesion development in the aorta (from 1.7±0.22 to 0.21±0.037 mm 2 ) and aortic sinus (from 101 000±7800 to 27 000±2900 μm 2 ) of LDLR −/− mice fed a Western-type diet for 3 months. Rimonabant also reduced plasma levels of the proinflammatory cytokines MCP-1 and IL12 by 85% ( P P 2 , 49% reduction, P Conclusions— These results show that rimonabant has antiatherosclerotic effects in LDLR −/− mice. These effects are partly unrelated to serum cholesterol modulation and could be related to an antiinflammatory effect. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|